ISA Pharmaceuticals long term study confirms efficacy of our T-cell activating immunotherapy in combination with checkpoint inhibitor
Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (ISA101b + anti-PD1) Deep and durable responses have a profound positive effect on patient prognosis with patients disease-free for more than 44 months Improved tumour infiltration by immune cells predicted response to therapy Oegstgeest, March 1, 2022 – ISA today announces the publication of […]
